A COMPARATIVE STUDY OF TENELIGLIPTIN VERSUS HYDROXYCHLOROQUINE AS ADD ON THERAPY IN UNCONTROLLED TYPE-II DIABETES MELLITUS PATIENTS

KRUNAL NATVARLAL CHAUHAN; ALKA YADAV; ANURAG JAIN; VIPIN KUMAR; RAHUL KUMAR PAL; JITENDRA KUMAR DONERIA

doi:10.22159/ajpcr.2024v17i12.53084

Authors

KRUNAL NATVARLAL CHAUHAN Department of Pharmacology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India
ALKA YADAV Department of Pharmacology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India
ANURAG JAIN Department of Pharmacology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India
VIPIN KUMAR Department of Pharmacology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India.
RAHUL KUMAR PAL Department of Pharmacology, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India
JITENDRA KUMAR DONERIA Department of Medicine, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2024v17i12.53084

Keywords:

Type 2 diabetes mellitus, Teneligliptin, Hydroxychloroquine, Glycated hemoglobin reduction, Insulin resistance, Hyperglycemia, Efficacy, Safety

Abstract

Objectives: This study aimed to compare the efficacy and safety of teneligliptin versus hydroxychloroquine (HCQ) as add-on therapy in uncontrolled T2DM patients. To measure the safety and efficacy of Teneligliptin and Hydroxychloroquine as add on therapy in uncontrolled type-2 diabetes mellitus patients. To compare the safety and efficacy of Teneligliptin and Hydroxychloroquine during the study. To assess the Glycaemic control in patients of Type-2 diabetes mellitus before treatment and after treatment.

Methods: This randomized, Observational and Prospective study enrolled 124 uncontrolled T2DM patients who were inadequately controlled on Metformin and Glimepiride therapy. Patients were randomly assigned to receive either teneligliptin (20mg/day) or HCQ (400mg/d ay) as add-on therapy for week 4,12 and 24 weeks. The primary outcome was the change in HbA1c from baseline to week 24.

Results: Both Teneligliptin and HCQ significantly reduced HbA1c levels from baseline, with a greater reduction observed in the Teneligliptin group (p < 0.001). Additionally, the Teneligliptin group demonstrated improved fasting blood sugar (FBS) and postprandial glucose (PPG) levels in comparison to Hydroxychloroquine.

Conclusion: This study suggests that Teneligliptin is a more effective and tolerable add-on therapy compared to Hydroxychloroquine in uncontrolled T2DM patients, highlighting its potential as a valuable treatment option for improving glycaemic control.

Downloads

Download data is not yet available.

References

Diabetes. Available from: https://www.who.int/news-room/fact-sheets/ detail/diabetes [Last accessed on 2021 Jun 10].

Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021 Nov 1;69(11):2932-8. doi: 10.4103/ijo. IJO_1627_21, PMID 34708726

Joseph A, Thirupathamma M, Mathews E, Alagu M. Genetics of type 2 diabetes mellitus in Indian and Global Population: A review. Egypt J Med Hum Genet. 2022 Sep 2;23(1):135. doi: 10.1186/s43042-022- 00346-1, PMID 37192883

Sheiner LB. Clinical pharmacology and the choice between theory and empiricism. Clin Pharmacol Ther. 1989 Dec;46(6):605-15. doi: 10.1038/clpt.1989.195, PMID 2689043

Ramachandran A. Know the signs and symptoms of diabetes. Indian J Med Res. 2014 Nov 1;140(5):579-81. PMID 25579136

Mane K, Chaluvaraju KC, Niranjan MS, Zaranappa TR, Manjuthej TR. Review of insulin and its analogues in diabetes mellitus. J Basic Clin Pharm. 2012 Mar;3(2):283-93. doi: 10.4103/0976-0105.103822, PMID 24826038

Najmutdinova DK, Urinbayevada. Efficiency of analogs of insulin in patients with type 2 diabetes mellitus with cardiovascular complications. Comparative analysis of patients. Innov Modern Educ Syst. 2021 Oct 25;47.

Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus: A new job for an old drug? Ann Intern Med. 1990 May 1;112(9):678-81. doi: 10.7326/0003-4819-112- 9-678, PMID 2110430

Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007 Jul 11;298(2):187-93. doi: 10.1001/ jama.298.2.187, PMID 17622600

Mudaliar S. New frontiers in the management of type 2 diabetes. Indian J Med Res. 2007 Mar 1;125(3):275-96. PMID 17496356

Szosland K, Lewinski A. Insulin resistance - “the good or the bad and ugly”. Neuro Endocrinol Lett. 2018 Jan 1;39(5):355-62. PMID 3066434012. Baidya A, Kumar M, Pathak SK, Ahmed R. Study of comparative effect of hydroxychloroquine and vildagliptin on glycaemic efficacy and HbA1cin type 2 diabetes patients who were inadequately controlled with metformin and glimepiride dual therapy. J Med Sci Clin Res. 2018;6(4):409-15.

Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med. 1998 Jul;15(7):539-53. doi: 10.1002/(SICI)1096- 9136(199807)15:7<539:AID-DIA668>3.0.CO;2-S, PMID 9686693

Venyo AK. Diabetes mellitus: A review and update. J Ophthalmol Res Rev Rep. 2023;144(4):22-4.

Kumar V, Singh MP, Singh AP, Pandey MS, Kumar S, Kumar S. Efficacy and safety of hydroxychloroquine when added to stable insulin therapy in combination with metformin and glimepiride in patients with type 2 diabetes compare to sitagliptin. Int J Basic Clin Pharmacol. 2018 Oct;7(10):1959-64.

Chakravarti HN, Nag A. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. J Endocrinol Invest. 2021 Mar;44(3):481-92. doi: 10.1007/s40618-020-01330-5, PMID 32594451

Kumar A, Prakash AS. Effectiveness and safety of hydroxychloroquine compared to teneligliptin in uncontrolled T2DM patients as add-on Therapy. J ASEAN Fed Endocr Soc. 2019;34(1):87-91. doi: 10.15605/ jafes.034.01.13, PMID 33442141